Arie Belldegrun's vision for Ginkgo comes into view, as the now $15B company teams with Biogen on gene therapy
When Arie Belldegrun toured Ginkgo Bioworks’ facilities to see whether he wanted to take them public with his SPAC, Belldegrun couldn’t stop talking about the potential to use Ginkgo’s synthetic biology technology in cell and gene therapy — an odd choice, given that Ginkgo had never done anything in cell and gene therapy.
On Friday, though, a week after Ginkgo and Belldegrun’s Soaring Eagle Acquisition Corp. merged in a record-setting deal, they got into the game. They announced an agreement with Biogen to improve the manufacturability of the AAV vectors the large biotech is developing for gene therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.